Objectives

• Lead radiation medicine through accelerator-based radioisotope/radiopharmaceuticals and treatment system (BNCT)

Research Areas

• Operate cyclotron, develop and distribute radioisotopes
• Develop diagnostic and therapeutic radiopharmaceuticals by disease
• Develop precision medical technologies based on medical imaging using radiopharmaceuticals
• Develop accelerator-based boron neutron capture therapy (BNCT) system and method
• Produce and distribute rare radiopharmaceuticals

Research Outcomes

• Operating 3 cyclotrons, produced, supplied, and developed radioisotopes and radiopharmaceuticals used in research and treatment
• Produced Astatine-211 (At-211), a radioisotope for cancer treatment, and achieved regular production following the establishment of separation and purification system
• Developed targeting device for alpha beam radiation and target station for therapeutic radioisotope production in 2021
• Produced and supplied future-leading PET radioisotopes (Cu-64, I-124, Zr-89)
• Provided support to 243 cases of beam radiation for RI production and beam radiation study by internal/external researchers (operating rate: 95% or higher)
• Approved phase 0 clinical trial for PET radiopharmaceutical “FC-303 (Florastamin)” for prostate cancer diagnosis in 2019, phase 3 clinical trial in progress
• Commercialized PET radiopharmaceutical “Alzavue” for the early diagnosis of Alzheimer’s disease in 2019 (first in Korea, fourth in the world)
• Implemented I-131-rituximab radioimmunotherapy through clinical trial by investigators targeting patients not responding to the existing therapy or patients with recurring lymphoma based on approval from the Ministry of Food and Drug Safety since 2004 (first and only in Korea)
• Assessment on the Impact of Micro Plastic on the Living Body Using Radioisotope:
  Verified absorption pathways of micro plastic and potential for causing autism spectrum disorder as the first in the world
• Completed the 250kV high-voltage load test on the independently developed 500keV proton tandem accelerator model, succeeded in beam radiation (Jun. 17, 2022)
• Implementing joint study for electrostatic accelerator based on technology transfer contract (2019 - 2022) with the National Atomic Energy Commission of Argentina (CNEA)